• Applied Use-Cases for Angiotensin 1/2 (5-7) in RAS Research

  2026-04-28

  Angiotensin 1/2 (5-7) empowers cardiovascular and viral pathogenesis research with its high purity, robust solubility, and validated activity. This guide translates the latest peer-reviewed insights and workflow best practices into actionable steps for bench scientists pursuing renin-angiotensin system signaling, blood pressure regulation, and emerging SARS-CoV-2 mechanistic studies.

• SB 431542: Strategic Modulation of TGF-β for Immuno-Oncology

  2026-04-28

  Explore how SB 431542, a selective ALK5 inhibitor from APExBIO, empowers translational researchers to dissect and modulate TGF-β-driven immune suppression. Drawing on new evidence from cryoablation studies in lung adenocarcinoma, this article provides mechanistic insight, protocol guidance, and strategic outlooks for integrating SB 431542 into tumor immunology and translational workflows.

• ABT-888 (Veliparib): Unlocking DNA Repair Inhibition in Tran

  2026-04-27

  This thought-leadership article provides a deep mechanistic and strategic perspective on ABT-888 (Veliparib) as a PARP1/2 inhibitor in translational cancer research. It integrates the latest findings on DNA damage response, frames the competitive and clinical landscape, and offers actionable guidance for leveraging ABT-888 in preclinical models of colorectal cancer and MSI tumors.

• Canagliflozin Hemihydrate: Precision Tool for Glucose Resear

  2026-04-27

  Canagliflozin hemihydrate empowers metabolic researchers with exceptional selectivity for dissecting renal glucose reabsorption and SGLT2 pathways. This guide delivers actionable workflows, protocol optimizations, and troubleshooting strategies—grounded in the latest screening evidence and comparative insights.

• Reliable Neurotoxicity Modeling with Amyloid Beta-peptide (2

  2026-04-26

  This article provides scenario-driven, evidence-based guidance for applying Amyloid Beta-peptide (25-35) (human) (SKU A1039) in neurodegenerative disease research. Addressing common lab challenges in cell viability and neurotoxicity assays, we demonstrate how SKU A1039 supports reproducible, high-sensitivity Alzheimer's disease modeling. Practical protocol parameters, product selection insights, and data interpretation advice are anchored in recent literature and validated workflows.

• Trichostatin A (TSA): Epigenetic Control Beyond Cancer Model

  2026-04-25

  Explore how Trichostatin A (TSA) enables advanced epigenetic regulation, bridging cancer research and regeneration biology. This article provides unique, protocol-driven insights for leveraging TSA in precise histone modification studies.

• Bismuth Subsalicylate: Technical Guidance for GI Research Wo

  2026-04-24

  Bismuth Subsalicylate (SKU A8382) enables reproducible modulation of inflammation pathways and gastrointestinal disorder modeling in preclinical research. This compound is best suited for assays probing prostaglandin synthase inhibition and gastrointestinal protection, but should not be used for diagnostic or clinical applications. Careful attention to solubility, storage, and workflow integration is essential to maximize reliability.

• G007-LK Tankyrase 1/2 Inhibitor: Precision in Wnt Pathway Re

  2026-04-24

  G007-LK tankyrase 1/2 inhibitor empowers researchers to dissect Wnt/β-catenin and Hippo signaling with nanomolar precision, transforming APC mutation colorectal cancer and hepatocellular carcinoma models. This article delivers actionable workflows, troubleshooting insights, and protocol enhancements to maximize the reliability of G007-LK in advanced cancer biology.

• hiPSC-Derived Intestinal Organoids Enhance Pharmacokinetic M

  2026-04-23

  This study introduces a streamlined protocol for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids with robust self-renewal and differentiation capacity. These organoids closely recapitulate human intestinal epithelial function, offering a more predictive in vitro model for pharmacokinetic studies and drug metabolism research.

• EZ Cap™ Firefly Luciferase mRNA: Precision in Reporter Assay

  2026-04-23

  EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure redefines sensitivity and stability in gene regulation and translation assays. Its optimized features enhance mRNA delivery, enabling robust in vivo bioluminescent imaging and reproducible molecular workflows.

• DiscoveryProbe™ Protease Inhibitor Library: Reliable Solutio

  2026-04-22

  This article explores real-world laboratory challenges in cell viability, apoptosis, cancer, and infectious disease research, showing how the DiscoveryProbe™ Protease Inhibitor Library (SKU L1035) addresses reproducibility, sensitivity, and workflow integration. Evidence-based Q&A scenarios guide researchers toward robust, data-driven protease inhibition strategies and vendor selection.

• Ferroptosis-Driven Prognostic Signature and Atorvastatin in

  2026-04-22

  This study introduces a four-gene ferroptosis-related prognostic signature for hepatocellular carcinoma (HCC) and experimentally identifies Atorvastatin as a potent inducer of ferroptosis in HCC models. These findings provide a mechanistic rationale for integrating ferroptosis modulation into future HCC therapeutic strategies.

• JSH-23: Potent NF-κB Inhibitor for Inflammation Research

  2026-04-21

  JSH-23 is a selective NF-κB inhibitor that blocks p65 nuclear translocation, enabling precise dissection of inflammatory pathways. It is widely used for NF-κB signaling pathway studies and validated in cisplatin-induced acute kidney injury models. The compound is suitable for both cell-based and in vivo protocols in inflammation research.

• Adefovir Dipivoxil: Sustained HBV Suppression and Resistance

  2026-04-21

  This review by Hadziyannis and Papatheodoridis establishes adefovir dipivoxil as a potent, well-tolerated nucleotide analog for chronic hepatitis B, including lamivudine-resistant cases. The paper's multi-year efficacy and low resistance rates provide a benchmark for HBV antiviral agent evaluation and protocol design.

• Disrupting c-MYC/G9a Axis: Co-targeting BRD4 and RAC1 in Bre

  2026-04-20

  This study demonstrates that simultaneous inhibition of BRD4 and RAC1 in breast cancer subtypes disrupts the c-MYC/G9a/FTH1 signaling axis, reduces tumor growth and stemness, and downregulates HDAC1. These findings provide mechanistic insight into epigenetic regulation in breast cancer and highlight the value of targeting histone methyltransferase activity in translational cancer research.

451 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page